Primair centraal zenuwstelsel non-Hodgkin lymfoom

More documents

Recommendations

Info

5 10 15 20 25 30 35 40 53. Johnson GJ, Oken MM, Anderson JR, O'Connell MJ, Glick JH. Central nervous system relapse in unfavourable-histology non-Hodgkin's lymphoma: is prophylaxis indicated? Lancet 1984; 2:685-7. 54. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91:1178-84. 55. Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non- Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000; 11:685-90. 56. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21:20-7. 57. MacKintosh FR, Colby TV, Podolsky WJ, Burke JS, Hoppe RT, Rosenfelt FP, et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 1982; 49:586-95. 58. Logsdon MD, Ha CS, Kavadi VS, Cabanillas F, Hess MA, Cox JD. Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997; 80:477-88. 59. McDonald AC, Nicoll JA, Rampling RP. Non-Hodgkin's lymphoma presenting with spinal cord compression; a clinicopathological review of 25 cases. Eur J Cancer 2000; 36:207-13. 60. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293:161-6. 61. van Besien K, Forman A, Champlin R. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol 1997; 8:515- 24. 62. Paulus JA, Bos GM, Lowenberg B, Van Den Bent MJ. [Treatment results and the prognosis in patients with localization of non-Hodgkins-lymphoma in the central nervous system]. Ned Tijdschr Geneeskd 1998; 142:2196-200. 63. Tomita N, Kodama F, Sakai R, Koharasawa H, Hattori M, Taguchi J, et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymphoma 2000; 38:335- 43. 64. Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43:1783-8. 65. Bleyer WA, Dedrick RL. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 1977; 61:703-8. CZS LYMFOMEN 14
Bijlage 1 Liquor MTX spiegels “zonder neurotoxiciteit” na intrathecale/intraventriculaire toediening 5 Dag 2 1.7 x 10 -7 M ≅ 75.3 µg/L 3 3.4 x 10 -8 15.1 4 8.6 x 10 -9 3.8 5 5.7 x 10 -9 2.5 6 1.4 x 10 -9 0.6 CZS LYMFOMEN 15
Page 1 and 2: Centraal-zenuwstelsellymfomen H. Ha
Page 3 and 4: 5 besloten. Bij aanwezigheid van ui
Page 5 and 6: 5 Bij recidieven na radiotherapie e
Page 7 and 8: 5 10 vertonen. De cauda equina en d
Page 9 and 10: 5 10 uitgesproken voor toediening v
Page 11 and 12: Referenties 5 10 15 20 25 30 35 40
Page 13: 5 10 15 20 25 30 35 40 45 50 35. Sc

Primair centraal zenuwstelsel non-Hodgkin lymfoom

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?